Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07028970

Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection

Sponsor: Nanjing IASO Biotechnology Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a multicenter, open-label, single-arm, long-term follow-up clinical study. All patients who have received Equecabtagene Autoleucel Injection treatment will be enrolled.

Key Details

Gender

All

Age Range

Any - Any

Study Type

OBSERVATIONAL

Enrollment

1500

Start Date

2024-12-15

Completion Date

2043-12

Last Updated

2025-06-19

Healthy Volunteers

No

Interventions

OTHER

No Intervention (subjects were previously treated with Equecabtagene Autoleucel Injection) )

This study is observational study and all participants will be obsreved with no intervention.

Locations (6)

Peking University First Hospital

Beijing, China

People's Hospital of Peking Universit

Beijing, China

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences

Tianjin, China

Tianjin Medical University General Hospital

Tianjin, China

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, China

Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University

Zhengzhou, China